Aslan Pharmaceuticals Pte Ltd (6497):製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Aslan Pharmaceuticals Pte Ltd (6497) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C10647
◆発行会社(調査会社):GlobalData
◆発行日:2018年11月
◆ページ数:65
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:シンガポール
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Aslan Pharmaceuticals Pte Ltd (Aslan), a subsidiary of Aslan Pharmaceuticals Ltd, is a biotechnology company that offers immuno-oncology agents and targeted therapies. The company’s pipeline products comprise varlitinib, ASLAN002, ASLAN003 and ASLAN004. Its ASLAN002 is a small molecule inhibitor of RON and cMET receptor tyrosine kinases for the treatment of gastric and breast cancer. Aslan’s ASLAN003 is a small molecule inhibitor of dihydroorotate dehydrogenase inhibitor to treat tumors; and ASLAN004 is a full human monoclonal antibody that reduces exacerbation in moderate or severe asthma and improves the functioning of lungs. It operates in Singapore, Taiwan, China and Australia. Aslan is headquartered in Singapore City, Singapore.

Aslan Pharmaceuticals Pte Ltd (6497) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Aslan Pharmaceuticals Pte Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Aslan Pharmaceuticals Pte Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Aslan Pharmaceuticals Pte Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Aslan Pharmaceuticals Pte Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Aslan Pharmaceuticals Pte Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Aslan Pharmaceuticals Pte Ltd, Pharmaceuticals & Healthcare, Deal Details 12
Venture Financing 12
Aslan Pharma Raises USD23 Million in Venture Financing 12
Aslan Pharma Raises Additional USD9 Million in Venture Financing 14
Aslan Pharma Raises USD34 Million in Series C Financing 16
Aslan Pharma Raises US$22 Million In Series B Financing 18
Partnerships 20
Aslan Pharma Enters into Agreeement with Cancer Science Institute Of Singapore and National University Cancer Institute 20
Aslan Pharma Enters into MoU with National Cancer Centre Singapore 21
ASLAN Pharma Enters into Agreement with ACT Genomics 22
Licensing Agreements 23
Aslan Pharma Enters into Licensing Agreement with Array BioPharma 23
ASLAN Pharma Enters into Licensing Agreement with Nanyang Technological University 24
ASLAN Pharma Enters into Licensing Agreement with Agency for Science, Technology and Research 25
Hyundai Pharma Enters into Licensing Agreement with Aslan Pharma 26
Aslan Pharma Enters Into Licensing Agreement With CSL For CSL-334 27
Aslan Pharma Expands Licensing Agreement with Almirall for LAS186323 28
Equity Offering 29
Aslan Pharma Raises USD42.2 Million in Public Offering of Shares 29
Aslan Pharma Plans to Raise USD84 Million in Public Offering of Shares 31
Aslan Pharma Plans to Raise Funds through Private Placement of Shares 32
Aslan Pharma Raises USD33.2 Million in IPO 33
Aslan Pharmaceuticals Pte Ltd – Key Competitors 34
Aslan Pharmaceuticals Pte Ltd – Key Employees 35
Aslan Pharmaceuticals Pte Ltd – Locations And Subsidiaries 36
Head Office 36
Other Locations & Subsidiaries 36
Recent Developments 37
Financial Announcements 37
Aug 06, 2018: Aslan pharmaceuticals reports second quarter 2018 financial results and provides corporate update 37
Corporate Communications 38
Jan 23, 2017: Aslan Pharmaceuticals Receives Approval To List On Taipei Exchange 38
Product News 39
08/31/2017: ASLAN Pharmaceuticals Announces First Patient Enrolled in a Global Phase 2/3 Study for Varlitinib in Gastric Cancer 39
08/10/2018: ASLAN Pharmaceuticals completes recruitment for global phase 2 study for Varlitinib in first line gastric cancer 40
05/17/2018: ASLAN Pharmaceuticals to Present Two Posters on Varlitinib at ASCO 41
01/31/2018: ASLAN Pharmaceuticals sponsors Cholangiocarcinoma Foundation Annual Conference 2018 42
01/24/2017: Aslan Pharmaceuticals To Present At The Cholangiocarcinoma Foundation Annual Conference 2017 43
01/18/2018: ASLAN Pharmaceuticals Appoints Stephen Doyle as Head of China 44
Product Approvals 45
Aug 20, 2018: ASLAN Pharmaceuticals granted Orphan Drug Designationby the FDA for ASLAN003 for the treatment of acute myeloid leukaemia 45
Feb 19, 2017: ASLAN Pharmaceuticals receives Orphan Drug Designation in Korea for varlitinib (ASLAN001) in biliary tract cancer 46
Clinical Trials 47
Oct 09, 2018: Aslan Pharmaceuticals to present poster on Varlitinib at European Society for Medical Oncology congress 47
Sep 17, 2018: ASLAN Pharmaceuticals Provides Update on Timelines for Clinical Trial of Varlitinib in Biliary Tract Cancer in China 48
Jul 03, 2018: Aslan Pharmaceuticals Submits Clinical Trial Authorisation Application For First In Man Studies For ASLAN004 49
Apr 17, 2018: ASLAN Pharmaceuticals Announces Presentation of New Pre-Clinical Data on Varlitinib in Hepatocellular Carcinoma at AACR 50
Jan 08, 2018: ASLAN Pharmaceuticals announces shortened timeline to commercialisation for varlitinib in China 51
Jan 02, 2018: Aslan Pharmaceuticals Abstract On Varlitinib Wins Best Poster At ESMO Asia 2017 52
Nov 13, 2017: Aslan Pharmaceuticals Receives IND Approval In Singapore To Initiate Phase 2 Study Of ASLAN003 In Acute Myeloid Leukaemia 53
Nov 08, 2017: ASLAN Pharmaceuticals Announces Poster Presentation at ESMO Asia Congress 2017 54
Sep 07, 2017: Aslan Pharmaceuticals Announces Initiation Of First Clinical Study In Hepatocellular Carcinoma For Varlitinib 55
Jun 29, 2017: Aslan Pharmaceuticals Announces First Patient Enrolled In Global Pivotal Treetopp Study For Varlitinib In Biliary Tract Cancer 56
Jun 12, 2017: Aslan Pharmaceuticals Announces MTD For Varlitinib In Combination With Chemotherapies Commonly Used In First Line Gastric Cancer 57
Jun 07, 2017: Aslan Pharmaceuticals Announces New Positive Data Identifying ASLAN003 As A Novel Therapeutic Agent In Acute Myeloid Leukaemia 58
Jun 02, 2017: Aslan Pharmaceuticals Announces Publication of New Varlitinib Data in Metastatic Solid Tumours at ASCO 59
Jun 01, 2017: Aslan Pharmaceuticals Receives Clinical Trial Authorisation To Initiate Pivotal Study Of Varlitinib In Gastric Cancer 60
May 18, 2017: New Data On Varlitinib Published At 2017 Annual Meeting Of American Society Of Cancer Oncology 61
Apr 25, 2017: ASLAN Pharmaceuticals Initiates Global Pivotal Study For Varlitinib In Biliary Tract Cancer 62
Feb 13, 2017: Aslan Pharmaceuticals Announces First Patient Enrolled In Phase 1 Study Of Varlitinib In Japan 63
Feb 09, 2017: ASLAN Pharmaceuticals reports positive top-line results for phase 2 clinical trial of varlitinib in metastatic breast cancer 64
Appendix 65
Methodology 65
About GlobalData 65
Contact Us 65
Disclaimer 65

List of Tables
Aslan Pharmaceuticals Pte Ltd, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Aslan Pharmaceuticals Pte Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Aslan Pharmaceuticals Pte Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Aslan Pharmaceuticals Pte Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Aslan Pharmaceuticals Pte Ltd, Deals By Therapy Area, 2012 to YTD 2018 9
Aslan Pharmaceuticals Pte Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Aslan Pharma Raises USD23 Million in Venture Financing 12
Aslan Pharma Raises Additional USD9 Million in Venture Financing 14
Aslan Pharma Raises USD34 Million in Series C Financing 16
Aslan Pharma Raises US$22 Million In Series B Financing 18
Aslan Pharma Enters into Agreeement with Cancer Science Institute Of Singapore and National University Cancer Institute 20
Aslan Pharma Enters into MoU with National Cancer Centre Singapore 21
ASLAN Pharma Enters into Agreement with ACT Genomics 22
Aslan Pharma Enters into Licensing Agreement with Array BioPharma 23
ASLAN Pharma Enters into Licensing Agreement with Nanyang Technological University 24
ASLAN Pharma Enters into Licensing Agreement with Agency for Science, Technology and Research 25
Hyundai Pharma Enters into Licensing Agreement with Aslan Pharma 26
Aslan Pharma Enters Into Licensing Agreement With CSL For CSL-334 27
Aslan Pharma Expands Licensing Agreement with Almirall for LAS186323 28
Aslan Pharma Raises USD42.2 Million in Public Offering of Shares 29
Aslan Pharma Plans to Raise USD84 Million in Public Offering of Shares 31
Aslan Pharma Plans to Raise Funds through Private Placement of Shares 32
Aslan Pharma Raises USD33.2 Million in IPO 33
Aslan Pharmaceuticals Pte Ltd, Key Competitors 34
Aslan Pharmaceuticals Pte Ltd, Key Employees 35
Aslan Pharmaceuticals Pte Ltd, Other Locations 36
Aslan Pharmaceuticals Pte Ltd, Subsidiaries 36

List of Figures
Aslan Pharmaceuticals Pte Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Aslan Pharmaceuticals Pte Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Aslan Pharmaceuticals Pte Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Aslan Pharmaceuticals Pte Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Aslan Pharmaceuticals Pte Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Aslan Pharmaceuticals Pte Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Aslan Pharmaceuticals Pte Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

★海外企業調査レポート[Aslan Pharmaceuticals Pte Ltd (6497):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Danaher Corp (DHR):医療機器:M&Aディール及び事業提携情報
    Summary Danaher Corp (Danaher) is a medical technology company which designs, manufactures and markets medical, professional, commercial and industrial products and services. It offers a wide range of testing instruments, communications solutions, water quality systems, medical diagnostics solutions …
  • Caterpillar Inc (CAT):企業の財務・戦略的SWOT分析
    Caterpillar Inc (CAT) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and …
  • San Leon Energy Plc (SLE):企業の財務・戦略的SWOT分析
    Summary San Leon Energy Plc (San Leon) is an oil and gas exploration and production company. It is engaged in acquiring, exploring and developing conventional and shale oil and gas assets across Europe and North Africa. The company holds interests in Durresi Block located in offshore Albania and inc …
  • RayBiotech Inc-製薬・医療分野:企業M&A・提携分析
    Summary RayBiotech Inc (RayBiotech) is a life science company that offers proteins, antibodies and immunological kits. The company’s products include antibody arrays, elisa, functional assays, antibodies and custom recombinant protein service. It provides services such as testing services, custom se …
  • Osprey Medical Inc (OSP)-医療機器分野:企業M&A・提携分析
    Summary Osprey Medical Inc (Osprey Medical) is a medical device company that designs, develops, and manufacturers proprietary devices and monitoring systems. The company provides contrast removal system, which is designed to provide cardiologists with an advanced level of CIN protection in high risk …
  • Tecomet Inc:医療機器:M&Aディール及び事業提携情報
    Summary Tecomet Inc (Tecomet) is a medical equipment company that manufactures and markets cases, implants and instruments. The company offers various implants which include acetabular cups, femoral heads, femoral stems, poly liners, femoral wraps, patellas, poly inserts, tibia trays, hooks, plates, …
  • Graham Holdings Co (GHC):企業の財務・戦略的SWOT分析
    Graham Holdings Co (GHC) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses …
  • Sims Metal Management Ltd:企業の戦略・SWOT・財務情報
    Sims Metal Management Ltd - Strategy, SWOT and Corporate Finance Report Summary Sims Metal Management Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service …
  • Sime Darby Berhad (SIME):企業の財務・戦略的SWOT分析
    Sime Darby Berhad (SIME) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses …
  • Valener Inc (VNR):企業の戦略的SWOT分析
    Valener Inc (VNR) - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and serv …
  • Steris PLC:企業の戦略・SWOT・財務情報
    Steris PLC - Strategy, SWOT and Corporate Finance Report Summary Steris PLC - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actio …
  • Duke Energy Corporation (DUK):石油・ガス:M&Aディール及び事業提携情報
    Summary Duke Energy Corp (Duke Energy) is an integrated energy utility that undertakes the generation, transmission, distribution and sale of electricity; transportation and sale of natural gas; and provision of related energy services in the Southeast and Midwest regions of the US. It also procures …
  • Pascal Biosciences Inc (PAS):製薬・医療:M&Aディール及び事業提携情報
    Summary Pascal Biosciences Inc (Pascal Biosciences), formerly BioMmune Technologies Inc is a biotechnology company that discovers and develops treatments in the field of immuno-oncology. The company develops targeted agents that enable the body's own immune system to recognize and attack cancers, in …
  • Pfizer Inc (PFE):企業の財務・戦略的SWOT分析
    Pfizer Inc (PFE) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the …
  • Straumann Holding AG (STMN):企業の財務・戦略的SWOT分析
    Straumann Holding AG (STMN) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakness …
  • Ubisoft Entertainment SA (UBI):企業の財務・戦略的SWOT分析
    Ubisoft Entertainment SA (UBI) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakn …
  • Yakult Honsha Co Ltd (2267):製薬・医療:M&Aディール及び事業提携情報
    Summary Yakult Honsha Co Ltd (Yakult) is a probiotics company that undertakes the development, manufacture and commercialization of probiotic and pharmaceutical products. The company’s product portfolio encompasses food and beverages such as fermented milk drinks, juice and others products; pharmace …
  • Cajun Industries, LLC:企業の戦略的SWOT分析
    Cajun Industries, LLC - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and …
  • Ikkuma Resources Corp (IKM):石油・ガス:M&Aディール及び事業提携情報
    Summary Ikkuma Resources Corp (Ikkuma), formerly PanTerra Resource Corp is an oil and gas exploration and development company that operates conventional and unconventional projects. The company conducts drilling operations in Foothills region of Alberta and British Columbia, Canada. It also gathers …
  • Aderans Co Ltd:企業の戦略・SWOT・財務分析
    Aderans Co Ltd - Strategy, SWOT and Corporate Finance Report Summary Aderans Co Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpora …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆